ATE142877T1 - Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie - Google Patents

Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie

Info

Publication number
ATE142877T1
ATE142877T1 AT92107865T AT92107865T ATE142877T1 AT E142877 T1 ATE142877 T1 AT E142877T1 AT 92107865 T AT92107865 T AT 92107865T AT 92107865 T AT92107865 T AT 92107865T AT E142877 T1 ATE142877 T1 AT E142877T1
Authority
AT
Austria
Prior art keywords
sleep disorders
melatonine
anesthesia
derivatives
treatment
Prior art date
Application number
AT92107865T
Other languages
English (en)
Inventor
Gabriele Biella
Franco Fraschini
Bojidar Stankov
Strambi Luigi Ferini
Original Assignee
I F L O Istituto Farmacologico
Franco Fraschini
Bojidar Stankov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I F L O Istituto Farmacologico, Franco Fraschini, Bojidar Stankov filed Critical I F L O Istituto Farmacologico
Application granted granted Critical
Publication of ATE142877T1 publication Critical patent/ATE142877T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT92107865T 1991-05-13 1992-05-11 Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie ATE142877T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Publications (1)

Publication Number Publication Date
ATE142877T1 true ATE142877T1 (de) 1996-10-15

Family

ID=11359886

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92107865T ATE142877T1 (de) 1991-05-13 1992-05-11 Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
AT95118386T ATE184792T1 (de) 1991-05-13 1992-05-11 2-bromomelatonin zur behandlung von schlafstörungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95118386T ATE184792T1 (de) 1991-05-13 1992-05-11 2-bromomelatonin zur behandlung von schlafstörungen

Country Status (9)

Country Link
US (1) US5430029A (de)
EP (2) EP0513702B1 (de)
JP (1) JPH05155769A (de)
AT (2) ATE142877T1 (de)
DE (2) DE69213814T2 (de)
DK (2) DK0713701T3 (de)
ES (2) ES2139132T3 (de)
GR (2) GR3022060T3 (de)
IT (1) IT1251544B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0641565B1 (de) * 1990-09-28 2000-03-15 I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi Kontrazeptives und Menstruationszyklus regulierendes Präparat mit onkostatischen Eigenschaften
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IT1262912B (it) * 1992-12-30 1996-07-22 Impiego della melatonina nella terapia della sclerosi sistemica, della sarcoidosi ed altro
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
US6180657B1 (en) 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
AU726758B2 (en) * 1993-11-18 2000-11-23 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
AU2310895A (en) * 1994-04-07 1995-10-30 Cemaf Novel spiro{indole-pyrrolidine} derivatives as melatoninergic agonists, method for preparing same and use thereofas a drug
CZ291349B6 (cs) * 1995-02-01 2003-02-12 Neurim Pharmaceuticals Ltd. Léčivo pro prevenci nebo léčbu závislosti na benzodiazepinech
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
CN1206996C (zh) * 1998-06-09 2005-06-22 武田药品工业株式会社 用于治疗或预防睡眠障碍的药物组合物
FR2787447B1 (fr) * 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000045832A2 (en) * 1999-02-05 2000-08-10 The Victoria University Of Manchester Regulation of anaesthesia
US6552064B2 (en) * 2000-09-19 2003-04-22 University Of Iowa Research Foundation Use of melatonin for induction of general anesthesia
US6638966B2 (en) 2000-09-19 2003-10-28 University Of Iowa Research Foundation Use of melatonin analogues for induction of general anesthesia
IL144900A (en) * 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and medicaments comprising it for use in treating primary insomnia and in the manufacture of such medicaments
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005063248A1 (en) * 2003-12-22 2005-07-14 Sepracor Inc. Modafinil combination therapy for improving sleep quality
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
JP2007523165A (ja) 2004-02-18 2007-08-16 セプレイコー インコーポレイテッド 睡眠の質を改善するためのドーパミン作動薬併用療法
US8053462B2 (en) 2004-03-08 2011-11-08 Masanori Somei Indole derivative and application thereof
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
RU2488392C2 (ru) * 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
KR102171965B1 (ko) 2012-01-26 2020-10-30 반다 파마슈티칼즈, 인코퍼레이티드. 일주기 리듬 장애의 치료
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CA3158157A1 (en) 2012-12-18 2014-06-26 Vanda Pharmaceuticals Inc. Use of tasimelteon in the treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
JP2025526852A (ja) * 2022-02-16 2025-08-15 ラ ファーマテック インコーポレイテッド 不眠症の治療のための新規医薬組成物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
FI900801A7 (fi) * 1987-08-17 1990-02-16 Nelson Res & Development Co Melantoniinianalogit

Also Published As

Publication number Publication date
EP0513702A2 (de) 1992-11-19
GR3022060T3 (en) 1997-03-31
ITMI911299A0 (it) 1991-05-13
ES2093735T3 (es) 1997-01-01
DE69213814D1 (de) 1996-10-24
EP0513702A3 (de) 1992-11-25
ES2139132T3 (es) 2000-02-01
EP0713701B1 (de) 1999-09-22
IT1251544B (it) 1995-05-17
EP0713701A1 (de) 1996-05-29
DK0513702T3 (da) 1996-12-30
ITMI911299A1 (it) 1992-11-13
ATE184792T1 (de) 1999-10-15
DE69213814T2 (de) 1997-04-03
DE69230046D1 (de) 1999-10-28
EP0513702B1 (de) 1996-09-18
JPH05155769A (ja) 1993-06-22
GR3032207T3 (en) 2000-04-27
DK0713701T3 (da) 2000-04-03
US5430029A (en) 1995-07-04
DE69230046T2 (de) 2000-05-31

Similar Documents

Publication Publication Date Title
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
FI934983A0 (fi) Kinuklidinderivat foer behandling av inflammatoriska och gastrointestinala sjukdomar
ATE447952T1 (de) Synergistische kombination von pumafentrine und salmeterol
NO890259L (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
IL85627A (en) Pharmaceutical compositions for treatment of disorders of ischemic origin comprising metformin and its salts
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
ATE367387T1 (de) Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE69426471D1 (de) Verwendung von Sulodexid und von Arzneimitteln, die dieses enthalten, zur Behandlung der diabetischen Nephropathie
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
DE69120933D1 (de) Topische Anwendung von Glycosaminoglykane zur Prävention und Behandlung der Zervikal- oder Vaginalerkrankungen
EA200200656A1 (ru) НОВЫЕ ТЕРАПЕВТИЧЕСКИЕ КОМБИНАЦИИ (S)-2-(БЕНЗИЛАМИНОМЕТИЛ)-2,3,8,9-ТЕТРАГИДРО-7H-1,4-ДИОКСИН [2,3-е]ИНДОЛ-8-ОНА И НЕЙРОЛЕПТИКОВ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ПСИХОТИЧЕСКИХ РАССТРОЙСТВ
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
ATE230608T1 (de) Verwendung von bradykinin-antagonisten zur herstellung von arzneimitteln zur behandlung und prävention der alzheimer'schen krankheit